Healthy
Conditions
Brief summary
The primary objective of the study (Main Part 2) was to investigate whether and to which extent a combination of multiple oral doses (steady state conditions) of 75 mg of clopidogrel q.d. (after a loading dose of 300 mg) and multiple doses of 150 mg of dabigatran etexilate b.i.d. at steady state affects pharmacokinetic and pharmacodynamic parameters of dabigatran etexilate and clopidogrel. The objective of the preceding Pilot Part 1 of the study was to explore the effect of a single dose of 300 mg clopidogrel administered after multiple doses of 75 mg and 150 mg dabigatran had reached steady state, regarding safety as well as pharmacokinetic and pharmacodynamic parameters. The Main Part 3 of the study moreover was to compare intra-individually the effects of a single dose of 600 mg clopidogrel with the same dose, 600 mg clopidogrel, given additionally to multiple doses of 150 mg dabigatran in steady state condition with respect to safety and pharmacokinetic and pharmacodynamic parameters.
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male subjects according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), body temperature, 12-lead electrocardiogram, clinical laboratory tests 2. Age ≥18 and Age ≤40 years 3. Body mass index (BMI) ≥18.5 and ≤29.9 kg/m2 (Body Mass Index) 4. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.
Exclusion criteria
1. Any gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 2. Subjects who in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of: * Hemorrhagic disorders or bleeding diathesis * Occult blood in faeces or haematuria * Trauma or surgery within the last month or as long as an excessive risk of bleeding persists after these events, or planned surgery during trial participation * History of arteriovenous malformation or aneurysm * History of gastroduodenal ulcer disease, gastrointestinal haemorrhage and haemorrhoids * History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intraarticular bleeding * Use of drugs that may interfere with haemostasis during trial conduct (e.g.acetyl salicylic acid or other non-steroidal anti-inflammatory drugs) 3. Relevant surgery of gastrointestinal tract 4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 5. History of relevant orthostatic hypotension, fainting spells or blackouts 6. Chronic or relevant acute infections 7. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator 8. Intake of any medication within four weeks of first dosing 9. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial, especially inhibitors or inducers of P-gp, CYP3A4 CYP2C9 or CYP2C19 10. Intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, nonsteroidal anti-rheumatic drugs, cumarin etc. within 10 days prior to administration or during the trial 11. Participation in another trial with an investigational drug within one month prior to administration or during the trial 12. Alcohol abuse (more than 60 g/day on a regular basis) 13. Drug abuse 14. Within 5 days of study medication no intake of grapefruit, grapefruit juice, or products containing grapefruit juice, Seville oranges, garlic supplements, or St. John's Worth 15. Blood donation (more than 100 mL within four weeks prior to administration) 16. Excessive physical activities (within one week prior to administration or during the trial) 17. Any laboratory value outside the reference range that is of clinical relevance 18. Inability to comply with dietary regimen of study centre 19. Male subjects do not agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the study. Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two months)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Emax,IPA,0-24 (maximum percentage change - compared to baseline - in adenosine diphosphate-induced platelet aggregation after the loading dose of clopidogrel) | baseline, up to 19 days | — |
| AUCτ,ss (area under the concentration-time curve of the analyte in plasma over one dosing interval at steady state) | up to 19 days | for total dabigatran, clopidogrel and the inactive metabolite SR26334 |
| AUC0-24,1 (area under the concentration-time curve of the analyte in plasma over one dosing interval after the loading dose) | up to 19 days | for clopidogrel and the inactive metabolite SR26334 |
| Cmax,ss (maximum measured concentration of the analyte in plasma at steady state) | up to 19 days | for total dabigatran, clopidogrel and the inactive metabolite SR26334 |
| Cmax,1 (maximum measured concentration of the analyte in plasma after the loading dose) | up to 19 days | for total dabigatran, clopidogrel and the inactive metabolite SR26334 |
| AUECIPA,0-24 (area under the effect curve of inhibition of platelet aggregation after the first dose of clopidogrel) | up to 19 days | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CL/F (apparent clearance of the analyte in the plasma after extravascular administration) | up to 8 weeks | Clopidogrel and SR 26334 after the loading dose |
| Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose) | up to 8 weeks | Clopidogrel and SR 26334 after the loading dose |
| Cmax, ss | up to 8 weeks | free dabigatran after multiple dosing |
| AUCτ,ss | up to 8 weeks | free dabigatran after multiple dosing |
| AUC0-tz,ss (area under the concentration-time curve of the analyte in plasma from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| tz,ss (time of last measureable concentration of the analyte in plasma within the dosing interval τ at steady state) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| tmax,ss (time from last dosing to the maximum concentration of the analyte in plasma at steady state on day 4) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| tmin,ss (time from last dosing to the minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| tmax (time from dosing to the maximum concentration of the analyte in plasma) | up to 8 weeks | Clopidogrel and SR 26334 after the loading dose |
| MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| PTF (peak trough fluctuation) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| Cavg (average concentration of the analyte in plasma at steady state over a uniform dosing interval) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| AUECt1-t2 (area under the effect curve (baseline corrected by ratio)) | up to 8 weeks | for activated partial thromboplastin time, thrombin time and ecarin clotting time |
| ERmax (maximum effect ratio) | up to 8 weeks | for activated partial thromboplastin time, thrombin time and ecarin clotting time |
| tmax (time to maximum effect) | up to 8 weeks | for activated partial thromboplastin time, thrombin time and ecarin clotting time |
| Occurence of Adverse Events | up to 13 weeks | — |
| Assessment of Tolerability by investigator | up to 13 weeks | — |
| Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose) | up to 8 weeks | Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing |
| AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) | up to 8 weeks | Clopidogrel and SR 26334 after the loading dose |
| AUC0-tz (area under the concentration-time curve of the analyte in plasma from the time point 0 to the last quantifiable analyte plasma concentration) | up to 8 weeks | Clopidogrel and SR 26334 after the loading dose |
| λz (terminal rate constant in plasma) | up to 8 weeks | Clopidogrel and SR 26334 after the loading dose |
| t1/2 (terminal half-life of the analyte in plasma) | up to 8 weeks | Clopidogrel and SR 26334 after the loading dose |
| MRTpo (mean residence time of the analyte in the body after oral administration) | up to 8 weeks | Clopidogrel and SR 26334 after the loading dose |
Outcome results
None listed